ViewRay Inc announces that the VA Ann Arbor Healthcare System (VAAAHS) has selected a MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Lieutenant Colonel Charles S. Kettles VA Medical Center. The MRIdian system will enable the VA Ann Arbor Cancer Program to offer advanced MRI-guided radiation therapy technology to Veterans throughout the region who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
VAAAHS provides state-of-the-art healthcare services to Veterans at seven locations of care in southeast Michigan and northwest Ohio. The VA Ann Arbor Cancer Program has offered cancer care to Veterans from the tristate area since 1982. VAAAHS offers comprehensive, multidisciplinary care for Veterans with cancer and is one of 13 VA health systems nationally designated as a Center for Excellence for Prostate Cancer (Rahr Center of Excellence for Prostate Cancer), within a larger Precision Oncology Program. The Lieutenant Colonel Charles S. Kettles VA Medical Center joins the Louis Stokes Cleveland VA Medical Center offering treatment using MRIdian MRI-guided radiation therapy.
“We are proud to be working with VA Ann Arbor Healthcare System, a dedicated group of clinicians who are committed to bringing the most advanced radiation therapy to our Veterans,” said Paul Ziegler, Chief Commercial Officer at ViewRay. “MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) combines the benefits of real-time MRI visualization, on-table adaptive therapy, and automatic beam control, which allows clinicians to deliver precise radiation therapy treatment.”
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy
To date, over 22,000 patients have been treated with MRIdian. Currently, 51 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.
[Source(s): ViewRay Inc, PR Newswire]